Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates. by Paige, Ellie et al.
CIRCCVG/2018/002413/R1   1 
 
Interleukin-6 Receptor Signalling and Abdominal Aortic Aneurysm 
Growth Rates 
Ellie Paige*1,5 (PhD), Marc Clément*2 (PhD), Fabien Lareyre2,3,4 (MD PhD), Michael 
Sweeting5,6 (PhD), Juliette Raffort2,3,4 (MD PhD), Céline Grenier2 (PhD), Alison Finigan2 (-), 
James Harrison2 (BA), James E. Peters5,7 (MBChB PhD), Benjamin B. Sun5 (PhD), Adam S. 
Butterworth5,7,8 (PhD), Seamus C. Harrison7,9 (PhD FRCS), Matthew J. Bown9 (MBBCh PhD 
FRCS), Jes S. Lindholt10 (MD PhD DMSci), Stephen A. Badger11 (MD MCh FRCSEd), 
Iftikhar J. Kullo12 (MD), Janet Powell13 (MD PhD), Paul E. Norman14 (DS), D. Julian A. 
Scott15,16 (MD MBChB FRCS FRCSEd FEBVS), Marc A. Bailey15,16 (MBChB PhD), Stefan 
Rose-John17 (PhD), John Danesh5,7,8,18 (MBChB DPhil FRCP FFPH FMedSci), Daniel F. 
Freitag**5,7 (PhD), Dirk S. Paul**5,7 (PhD), Ziad Mallat**2,7,19 (MD PhD)  
 
*Joint first authors 
**Joint senior authors 
 
1 National Centre for Epidemiology and Population Health, Research School of Population 
Health, The Australian National University, Canberra, Australia 
2 Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK 
3 Université Côte d’Azur, Institut National de la Sante et de la Recherche Medicale, Centre 
Mediterranéen de Recherche Moleculaire, Nice, France 
4 University Hospital of Nice, France 
5 BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, 
University of Cambridge, Cambridge, UK 
6 Department of Health Sciences, University of Leicester, Leicester, UK 
7 British Heart Foundation Centre of Excellence, University of Cambridge School of Clinical 
Medicine, Cambridge, UK 
8 NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Cambridge, UK 
CIRCCVG/2018/002413/R1   2 
 
9 Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, 
University of Leicester, Leicester, UK 
10 Department of Cardiovascular and Thoracic surgery, Elitary Reserach Centre of 
Individualised Medicine in Arterial Disease, Odense University Hospital, Odense, Denmark 
11 Regional Vascular Surgery Unit, Belfast Health & Social Care Trust, Belfast, UK 
12 Department of Cardiovascular Medicine and the Gonda Vascular Center, Mayo Clinic, 
Rochester, Minnesota, USA 
13 Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, 
London, UK 
14 Medical School, University of Western Australia, Perth, Australia 
15 Leeds Vascular Institute, Leeds General Infirmary, Leeds, UK 
16 Leeds Institute of Cardiovascular & Metabolic Medicine, School of Medicine, University of 
Leeds, Leeds, UK 
17 Department of Biochemistry, Christian-Albrechts-University, Kiel, Germany 
18 Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK 
19 Institut National de la Santé et de la Recherche Médicale, Paris Cardiovascular Research 
Center, France 
 
Running title: IL-6R Signalling and AAA Growth Rates 
 
Correspondence: Professor Ziad Mallat 
   Department of Medicine,  
University of Cambridge 
Cambridge, CB2 0QQ, UK 
zm255@medschl.cam.ac.uk 
Tel: +44 (0) 1223 768678 
 
Total word count=6,661 
CIRCCVG/2018/002413/R1   3 
 
 
Subject codes: Animal Models of Human Disease; Inflammation; Epidemiology; Genetic, 
Association Studies; Aneurysm.   
CIRCCVG/2018/002413/R1   4 
 
Abstract  
Background: The Asp358Ala variant (rs2228145; A>C) in the interleukin-6 receptor (IL6R) 
gene has been implicated in the development of abdominal aortic aneurysms (AAAs), but its 
effect on AAA growth over time is not known. We aimed to investigate the clinical 
association between the IL6R-Asp358Ala variant and AAA growth, and to assess the effect 
of blocking the IL-6 signalling pathway in mouse models of aortic aneurysm rupture or 
dissection.  
Method: Using data from 2,863 participants with AAA from nine prospective cohorts, age- 
and sex-adjusted mixed-effects linear regression models were used to estimate the 
association between the IL6R-Asp358Ala variant and annual change in AAA diameter 
(mm/year). In a series of complementary randomised trials in mice, the effect of blocking the 
IL-6 signalling pathways was assessed on plasma biomarkers, systolic blood pressure, 
aneurysm diameter and time to aortic rupture and death. 
Results: After adjusting for age and sex, baseline aneurysm size was 0.55mm (95% 
confidence interval [CI]: 0.13, 0.98mm) smaller per copy of the minor allele [C] of the 
Asp358Ala variant. Change in AAA growth was -0.06mm per year [-0.18, 0.06] per copy of 
the minor allele; a result that was not statistically significant. Although all available worldwide 
data were used, the genetic analyses were not powered for an effect size as small as that 
observed. In two mouse models of AAA, selective blockage of the IL-6 trans-signalling 
pathway, but not combined blockage of both, the classical and trans-signalling pathways, 
was associated with improved survival (p<0.05).  
Conclusions: Our proof-of-principle data are compatible with the concept that IL-6 trans-
signalling is relevant to AAA growth, encouraging larger-scale evaluation of this hypothesis. 
 
Key words: interleukin-6 receptor; abdominal aortic aneurysm 
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Introduction 
Abdominal aortic aneurysms (AAAs) are defined as an enlargement of the aorta to ≥30mm 
diameter. They usually grow asymptomatically until rupture occurs, after which the survival 
of affected individuals is less than 20%.1 AAAs typically occur in mid-to-later life and more 
commonly in men (prevalence of 1-2%2, 3 compared to <1% in women4). Current standard of 
care is surgical intervention, either open surgery or endovascular repair. However, due to 
surgical risks vs. benefits, such interventions are generally recommended only for people 
with larger AAAs (diameter ≥55mm or >40mm and enlarging >10mm/year).5, 6 The growth 
rates of AAAs vary considerably between individuals7 and there is currently a lack of 
therapeutic options to slow or halt progression of AAAs.8 Inflammatory processes in the 
vessel wall may contribute to the progression of AAAs.9-11 For example, levels of circulating 
inflammatory markers including interleukin (IL)-6 are higher in prevalent AAA cases than 
controls12 and correlate with the size of AAA in cross-sectional studies.13 
 
IL-6 is a central coordinator of inflammatory responses by controlling the systemic 
inflammatory response in the liver and the activation and differentiation of leukocyte subsets, 
including macrophages and T cells. IL-6 signalling occurs in two different modes, termed 
“classical” (cis-) and trans-signalling. In classical signalling, binding of IL-6 to the membrane-
bound IL-6 receptor (mIL-6R) induces homodimerization with its co-receptor gp130, resulting 
in the phosphorylation of the transcription factors STAT3 and STAT1.14, 15 Hence, classical 
signalling is dependent on the membrane-bound form of the IL-6 receptor and occurs only in 
leukocyte subsets and hepatocytes that express this molecule. By contrast, trans-signalling 
occurs through a circulating soluble form of IL-6R (sIL-6R), which, if bound to IL-6, is able to 
stimulate cells expressing gp130, even in the absence of mIL-6R.14, 16 Because gp130 is 
almost ubiquitously expressed, IL-6 trans-signalling can occur in virtually any cell, although 
is probably active only during conditions of immunological stress.14, 16 
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A non-synonymous variant (Asp358Ala; rs2228145 A>C) in the IL6R gene, encoding the IL-
6 receptor, plays a critical role in IL-6 signalling. The minor allele [C] of this variant is 
associated with a reduced risk of several chronic conditions including coronary heart 
disease,17 atrial fibrillation,18 rheumatoid arthritis,19 type 1 diabetes,20 but an increased risk of 
asthma.21 The variant results in more efficient proteolytic cleavage of mIL-6R, thereby 
reducing levels of mIL-6R and dampening classical signalling.22, 23 Conversely, the variant 
increases levels of sIL-6R, although the exact effects of the variant on the trans-signalling 
pathway are unknown.20 A Mendelian randomisation study has previously implicated the 
rs2228145 in the causal pathway of AAA, with the minor allele [C] showing a protective 
effect for the risk of AAA and a combined endpoint of rupture or surgical intervention.12 
Licenced drugs are available that target the IL-6/IL-6 receptor pathway. However, evidence 
is needed that this pathway is associated with aneurysm progression or rupture in order to 
encourage repurposing drugs for use in patients with known AAA. 
 
The aims of this study were to: (1) to assess and quantify the effect of the functional IL6R 
variant on the progression of AAAs in population cohorts with prospective follow-up and 
standardized repeated measurements of AAA diameter; and (2) estimate the effect of 
blocking the IL-6 signalling pathway (i.e., either both classical and trans-signalling pathways 
or specifically the trans-signalling pathway) on time to aneurysm rupture in mouse models. 
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Material and methods 
Details on the materials and methods are available in the Supplemental Material. Because of 
the sensitive nature of the data collected for this study, requests to access the human AAA 
datasets from qualified researchers trained in human subject confidentiality protocols may be 
sent to the study leaders of each cohort. The experimental data that support the findings of 
this study are available from the corresponding author upon reasonable request. Each 
human AAA cohort was approved by a research ethics committee and all participants gave 
informed consent. Animal experiments were approved by the UK Home Office and 
performed under PPL PA4BDF775. The care and use of all mice in this study was carried 
out in accordance with the UK Home Office regulations under the Animals (Scientific 
Procedures) Act 1986. 
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Results 
Association of IL6R-Asp358Ala with AAA growth rate 
We studied a total of 2,863 participants across nine prospective cohorts, 91% of whom were 
men (mean age of 72 years; Table 1). AAA size was on average 43mm at baseline and 
participants had an average of four scans across an average of three years (Table 1). A 
summary of baseline characteristics by IL6R-rs2228145 (or proxy) genotype is given in 
Supplementary Table 1. On average, aneurysms grew by 1.88mm per year (95% CI: 1.79, 
1.96; Supplementary Figure 1). Baseline aneurysm size was 0.55mm (0.13, 0.98) smaller 
per copy of the minor allele [C] (Supplementary Figure 2). Among those with at least two 
measurements of aneurysm size (n=2,154), there was no statistically significant growth rate 
in AAA per minor allele (growth per minor allele= -0.06mm/year [-0.18, 0.06]) (Figure 1). All 
association analyses were adjusted for age and sex. Results were similar after adjustment 
for current smoking status, diabetes status, body mass index and aneurysm measurement 
method (Supplementary Figure 3). 
 
Similar results were observed when the analysis was restricted to those with a small 
aneurysm at baseline (growth= -0.10 mm/year [-0.23, 0.02] per copy of the minor allele; 
Supplementary Figure 4) or medium aneurysm at baseline (growth= -0.08 mm/year [-0.21, 
0.05] per copy of the minor allele; Supplementary Figure 5). We did observe an association 
between the Asp358Ala variant and time to surgery threshold after adjusting for age and sex 
(hazards ratio (HR)= 0.85 [0.73, 0.98] per copy of the minor allele; Supplementary Figure 
6a). The HR was in the same direction but became statistically non-significant in the subset 
of studies were we were able to additionally adjust for current smoking, diabetes status, 
body mass index and measurement method (HR=0.91 [0.77, 1.06]; Supplementary Figure 
6b). Overall change in AAA growth remained the same when individuals with only a single 
measure of aneurysm size were included in the model (n=2,691, growth=-0.06 mm/year [-
0.18, 0.06]; Supplementary Figure 7).
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Table 1. Baseline characteristics of the studies included in the human genetic analysis 
  N  Average 
no. 
scans 
 Average 
baseline  
AAA size 
(mm) 
 Average 
years 
between 
first and 
last scan  
 Males (%)  Average 
age 
(years)  
 Current 
smokers 
(%) 
 Ever 
smokers 
(%) 
 Diabetes 
(%) 
Belfast24  239  3  50  2.0  219 (92)  71.8   53 (22)  N/A  25 (10) 
Leeds25  543  6  49  2.8  464 (85)  74.3  132 (24)  490 (90)  66 (12) 
Leicester26  209  6  37  4.1  206 (99)  69.0  62 (30)  189 (90)  22 (11) 
Mayo  530  2  40  4.2  448 (85)  70.1  N/A  471 (89)  128 (24) 
St George27  79  2  56  1.4  71 (90)  77.2  16 (20)  51 (65)  4 (5) 
UKSAT28  466  7  45  2.5  387 (83)  68.8  160 (34)  439 (94)  14 (3) 
Viborg29  16  6  35  5.2  16 (100)  65.7  5 (31)  N/A  0 (0) 
Viva*29  523  2  41  1.4  523 (100)  71.0  215 (41)  320 (61)  57 (11) 
WA30  258  4  35  4.8  258 (100)  72.7  46 (18)  221 (86)  27 (10) 
TOTAL  2,863  4  43  3.1  2,592 (91)  71.7  689 (24)  2,181 (76)  343 (12) 
Notes: (1) Abbreviations: AAA= Abdominal Aortic Aneurysm; WA=Western Australia. (2) Missing data: sex=1(0.1%), age=3(0.1%), current 
smoking=566(20%), ever smoking=456 (16%), diabetes=98 (3%). *170 participants in Viva do not have data for date of measurement.  
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Inhibition of IL-6 signalling pathway in angiotensin II + anti-TGFβ mouse model 
We next tested the effect of blocking the IL-6 pathway in two distinct, previously 
characterised mouse models of AAA (Methods). In the angiotensin II + anti-TGFβ model, 
mice infused with anti-IL-6R (blocking both classical and trans-signalling pathways) 
demonstrated a significant increase of plasma concentration of IL-6, as compared to isotype 
treated mice, and this difference was sustained over the course of the experiment (Figure 
2A). We observed a reduction in plasma concentrations of serum amyloid A (SAA), a protein 
expressed in response to inflammation, after blocking IL-6R compared to the control mice 
(Figure 2B). Blocking IL-6R significantly reduced plasma concentration of IL-2 before and 
after the infusion and reduced concentration of IL-5 and chemokine ligand 1 (CXCL1) after 
the infusion (Figures 2A). After anti-IL-6R treatment, systolic blood pressure was significantly 
lower after the infusion compared to control treatment (Figure 2C). However, there was no 
significant difference in rate of aneurysm rupture between the anti-IL-6R treated and control 
groups (Figure 2D). Since there was no observed association with AAA rupture, we did not 
further assess the effect of blocking the IL-6R pathway on AAA growth. 
 
Selectively blocking the IL-6 trans-signalling pathway using sgp130Fc did not change the 
concentration of IL-6 (Figure 3A) or SAA (Figure 3B), but significantly induced IL-5 and 
reduced TNFα plasma concentration (Figure 3A). Although we observed no difference in 
systolic blood pressure between mice treated with sgp130Fc and the control mice (Figure 
3C), there was a significant reduction in aneurysm rupture after sgp130Fc treatment 
compared to control treatment (Figure 3D).  
 
Inhibition of IL-6 signalling pathway in elastase + anti-TGFβ mouse model 
Using the elastase + anti-TGFβ model, we found that blockage of the IL-6R pathway using 
anti-IL-6R resulted in significantly increased mortality (Figure 4A) induced by aortic rupture 
(Figure 4B) but there was no change in the diameter of the aneurysm at the end of the 
experiment (Figure 4C). αSMA+ density in the media was similar in the two groups of mice 
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(data not shown). There was also no change in the collagen content of the aortic wall (Figure 
4D) or the recruitment of myeloperoxidase positive (MPO+) cells (Figure 4E), but treatment 
with anti-IL-6R significantly enhanced the recruitment of CD3+ T cells in the aortic wall 
(Figure 4F). 
 
Blocking only the IL-6 trans-signalling pathway using sgp130Fc significantly increased 
survival (Figure 5A) by reducing aortic ruptures (Figure 5B), although at the end of the 
experiment there was no change in the aortic diameter between the treated and control mice 
(Figure 5C). Histological analysis of aortic samples revealed a significant increase in the 
collagen content of the arterial wall (Figure 5D) but no differences in αSMA+ density (data 
not shown), Ly6G+ (Figure 5E) and CD3+ T cell accumulation (Figure 5F) after sgp130Fc 
infusion, as compared to the control mice. Table 2 summarises the results of the different 
mouse models with a comparison to the human genetic data. 
 
Evaluation of the effect of IL6R-rs2228145 on a range of cardiovascular markers 
As would be expected, the minor allele of IL6R-rs2228145 was associated with increased 
plasma concentrations of IL-6 and sIL-6R. The variant was also associated with increased 
monocyte count, after correcting for multiple comparisons (p<1.389x10-3). At a nominal 
significance level (p<0.05), rs2228145-C was associated with reduced lymphocyte count, 
increased levels of the cytokines CXCL10, CXCL11 and IL1α, as well as CD6 (an important 
regulator of T cells), and reduced levels of MMP3 (a matrix metalloproteinase), TIMP4 (a 
metalloproteinase inhibitor), OPG (osteoprotegerin) and IGFBP1 (Supplementary Figure 8). 
In our analysis, the effects on plasma IL-2, IL-5, and CXCL1 levels, as well as on blood 
pressure, were not statistically significant. 
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Table 2. Comparison of results for the association between IL-6R and abdominal aortic aneurysm from human genetic analysis and 
mouse experimental models 
Model Inhibition of IL-6 
signalling 
Effect on AAA growth/ 
survival 
p-value of effect Other cardiovascular markers 
(p<0.05) 
Humans stratified for 
IL6R-Asp358Ala 
Minor allele associated 
with dampening of 
classical signalling. 
Effects on trans-signalling 
not clear. 
Non-significant change in 
AAA growth 
(0.06mm/year)* 
0.136 Increased IL-6, sIL-6R, CXCL10, 
CXCL11, IL1α and CD6; 
Reduced MMP3, OPG, IGFBP1, 
TIMP4 
Angiotensin II + anti-
TGFβ 
mouse model 
Both classical and trans-
signalling 
No difference in survival 1.000 Increased IL-6; 
Reduced SAA, IL-2, IL-5, CXCL1 
and SBP 
Only trans-signalling Improved survival 0.040 Increased IL-5; 
Reduced TNFα 
Elastase + anti-TGFβ 
mouse model 
Both classical and trans-
signalling 
Decreased survival 0.029 Increased recruitment of CD3+ T 
cells 
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Only trans-signalling Improved survival 0.024 Increased collagen content of the 
arterial wall 
*Effect indicated per copy of the IL6-R minor allele.  
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Discussion  
In a combined analysis of the available worldwide clinical genetic data on AAA growth, we 
observed no statistically significant decrease in annual AAA growth rates for carriers of the 
minor allele of the Asp358Ala variant (rs2228145) in the IL6R gene. While we did observe a 
15% decrease in the rate of reaching the surgery threshold of ≥55mm (HR=0.85 [0.73, 0.98] 
per copy of the minor allele), people with copies of the IL6R-Asp358Ala variant also had, on 
average, smaller baseline aneurysm diameters. Although we tried to account for this by 
allowing baseline hazards to vary depending on initial aneurysm size, some residual 
confounding is possible and could explain the observed results. In experimental data from 
mouse models, we found that selective blockade of the IL-6 trans-signalling pathway was 
associated with decreased aortic rupture and death. In exploratory analyses of 
cardiovascular and inflammatory biomarkers in healthy participants, we found that 
rs2228145-C was inversely associated with plasma levels of osteoprotegerin, matrix 
metalloproteinase-3 and metalloproteinase inhibitor-4 (p<0.05). Osteoprotegerin has 
previously been shown to promote matrix metalloprotease release from monocytes and 
vascular smooth muscle cells,31, 32 and aberrant aortic extracellular matrix remodelling has 
been suggested to play a key role in the pathogenesis of AAA.33 However, we note that 
further studies are needed to validate our biomarker data. Taken together, these human 
genetic, biomarker, and experimental murine findings are compatible with the concept that 
IL-6 trans-signalling is relevant to AAA growth, encouraging larger-scale evaluation of this 
hypothesis. 
 
If increased availability of sIL-6R results in a dampening of the IL-6 trans-signalling pathway, 
this may explain potential protective effects in AAA and is consistent with previously 
observed protective effects in mouse models of sepsis34 and pancreatic and lung failure.35 
As we found a consistent pattern of results when the trans-signalling pathway was 
selectively blocked in the mouse models, it suggests that this pathway could have a 
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detrimental effect on AAA growth (Figure 6). For example, the minor allele of the rs2228145 
variant may result in a local reduction of IL-6 trans-signalling in the abdominal vasculature, 
reducing AAA risk12 and, perhaps, AAA growth rates. Our observation of only a small, but 
statistically insignificant, decrease in annual AAA growth rates does not preclude meaningful 
clinical effects, since the growth rate reduction estimated from natural genetic variation does 
not necessarily relate to the magnitude of the benefit that might result from pharmacological 
treatment directed at the IL-6 trans-signalling pathway.36 Selective blocking of the IL-6 trans-
signalling pathway using sgp130Fc is being investigated in phase II clinical trials in patients 
with inflammatory bowel disease.14 
 
Nevertheless, apparent inconsistencies in our findings require further elucidation. For 
example, blockade of both the classic and trans-signalling IL-6 pathways using the animal-
equivalent (MR16-1) of tocilizumab had no effect on AAA rupture in the angiotensin II + anti-
TGFβ model, but it was associated with decreased survival in the elastase + anti-TGFβ 
model. These different outcomes could be explained by differences in the development of 
AAA in the different mouse models. The primary process of “aneurysm” formation in the 
angiotensin model is a medial dissection, which may be accentuated by elevations in blood 
pressure (even though high blood pressure is not the primary cause of medial dissection). 
Hence, the potential protection afforded by MR16-1 antibody in this model can at least in 
part be attributed to the significant reduction of blood pressure. In contrast, the elastase 
model does not involve medial dissection or elevations in blood pressure, but induces 
progressive remodelling, dilatation, and eventually transmural rupture of the artery wall, 
better mimicking AAA progression in humans.37, 38 
 
If selective blockade of the IL-6 trans-signalling pathway results in decreased aortic rupture, 
as suggested by our murine data, one might expect that blocking both the classic and trans-
signalling pathways would also result in decreased aortic rupture. However, we did not 
observe such a finding, perhaps due to competing downstream actions of the classic and 
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trans-signalling pathways. Such an explanation is consistent with our finding that IL-5 levels 
were increased and TNFα levels decreased when trans-signalling was selectively blocked, 
whereas blockade of both classic and trans-signalling pathways led to reductions in IL-5 
levels and no changes in TNFα. Our findings suggest that selective blockade of the IL-6 
trans-signalling pathway, compared to blockade of both IL-6 signalling pathways, results in 
different downstream cytokine profiles and potentially different effects on AAA progression. It 
is also possible that the blocking of both the classical signaling cascade (considered to have 
protective and regenerative cellular effects) and trans-signaling cascade (considered to have 
pro-inflammatory effects) cancelled each other out, leading to no detectable effect on AAA 
rupture. Further studies are needed to replicate and further characterise our findings. 
 
We undertook a range of sensitivity analyses to test assumptions underlying our longitudinal 
human genetic studies. We studied complementary murine models of AAA, including the 
elastase + anti-TGFβ mouse model that has been shown to more closely mimic the AAA 
growth and rupture patterns seen in humans. To generate new mechanistic hypotheses, we 
conducted exploratory studies of the IL6R-Asp358Ala variant in relation to cardiovascular 
and inflammatory plasma biomarkers recorded in healthy participants. The experimental 
mouse studies were conducted under severe conditions in which TGFβ was blocked. 
Although any effect of IL-6R signalling might have been easier to observe in a less severe 
model (aortic dilatation without rupture), a protective effect of the intervention in that setting 
would not provide assurance that the intervention will also be protective in a more severe 
model (aortic rupture). A treatment that limits aortic dilatation but does not reduce the risk of 
aortic rupture would have limited clinical relevance.  
 
Our study had potential limitations. It was powered to detect reductions in aneurysm growth 
of ~0.21mm per year or larger, much greater than the observed non-significant decrease of 
0.06mm per year. Future studies powered to see an effect the same size as that observed in 
the current study would need to recruit an additional ~21,500 participants (total participants 
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needed=24,444, Supplemental Material). This is unlikely to be achievable in the near future; 
alternative study methods using a composite phenotype for disease progression may be 
needed. Index event and survival bias, in which participants are selected into the study 
based on both having and surviving an event, may have biased the results towards the 
null.39 However, this bias is likely to be small (<10%).39 Further, ultrasound, the primary 
method used to assess AAA diameter in the included studies, has a margin of error of 2-
3mm,40 greater than the annual rate of aneurysm growth, making changes in growth difficult 
to detect. This might be why we observed an association between the IL6R-Asp358Ala 
variant and time to surgery threshold of ≥55mm but not when looking at continuous change 
in AAA size. Although we examined rupture rather than aortic diameter as the outcome in 
the mouse experimental models, our published data indicate that aortas that rupture have 
larger diameters or faster diameter progression than the ones that do not rupture.30  
 
It is also uncertain how well the results of our animal models translate to clinical disease. For 
example, an important difference is that IL-6 blockage is initiated before or at the time of 
disease development in the mice models of AAA, thereby not truly mimicking the treatment 
effects expected in humans, in which drugs to block IL-6 pathway would be started after 
disease onset. Blockade of the IL-6 signalling pathways in the angiotensin II + anti-TGFβ 
mouse model resulted in reproducible reductions in systolic blood pressure. Although 
tocilizumab has been anecdotally reported to improve pulmonary hypertension in 
Castleman’s disease,41, 42 the rs2228145 variant was not associated with changes in 
systemic blood pressure in healthy participants in a genome-wide association study. A large-
scale randomized trial found no difference in the number of hypertension events reported in 
those using tocilizumab compared to placebo.43, 44 Thus, the acute responses to 
pharmacological doses of angiotensin II in the mouse model may not faithfully reproduce the 
human setting of AAA. 
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Our study may have clinical implications. Tocilizumab is currently indicated in a few disease 
settings, including rheumatoid arthritis and giant cell arteritis, both of which are associated 
with an increased risk of aortic aneurysm.45, 46 The development of coronary artery 
aneurysms has also been reported in a non-placebo-controlled pilot study of tocilizumab in 
children with Kawasaki’s Disease.47 Findings from this pilot study in children, combined with 
our finding that blocking the IL-6 pathway using the animal-equivalent of tocilizumab was 
associated with decreased survival in the elastase + anti-TGFβ model, suggests that 
patients treated with tocilizumab for conditions associated with aortic aneurysm development 
should possibly be monitored for AAA. 
 
In conclusion, our proof-of-principle data are potentially compatible with the concept that IL-6 
trans-signalling is relevant to AAA growth, encouraging larger-scale evaluation of this 
hypothesis.  
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Figure titles and legends 
Figure 1: Sex- and age-adjusted change in abdominal aortic aneurysm growth rate 
(mm/year) per copy of the IL-6 minor allele 
Figure 2: Anti-IL6-R prevents angiotensin II induced hypertension but does not protect 
against aortic rupture induced by angiotensin II and anti-TGFβ infusion 
Mice were treated with anti-IL6-R or isotype control (n=22 mice/group) starting one week before 
angiotensin II and anti-TGFβ infusion. A – Plasma concentration of cytokines at day 0 (before 
angiotensin II and anti-TGFβ infusion) and day 7 to 14. *p<0.05 isotype vs anti-IL6-R; **p<0.01 
isotype vs anti-IL-6R; 2-way ANOVA followed by uncorrected fisher’s test. B – Plasma 
concentration of serum amyloid A (SAA) at day 0 (before angiotensin II and anti-TGFβ infusion) 
and day 7 to 14. ***p<0.05 isotype vs anti-IL6-R; 2-way ANOVA followed by uncorrected fisher’s 
test. C - Systolic blood pressure measurement using tail cuff at day 0 and day 7 after angiotensin II 
and anti-TGFβ infusion. ***p<0.001 isotype vs anti-IL-6R; 2-way ANOVA followed by uncorrected 
fisher’s test. D - Survival curves of mice after angiotensin II and anti-TGFβ infusion. All data for the 
generation of the graphs shown in Figure 2 were generated in two independent experiments and 
then pooled together. 
 
Figure 3: Selective blockage of the IL-6 trans-signalling pathway using sgp130 in the 
angiotensin II + anti-TGFβ model reduces aortic rupture 
Mice were treated with sgp130-Fc or human IgG1 Fc (Hum-Fc) (n=10 mice/group) starting one 
week before angiotensin II and anti-TGFβ infusion. A - Plasma concentration of cytokines at day 0 
(before angiotensin II and anti-TGFβ infusion) and day 7. *p<0.05 Hum-Fc vs sgp130; ***p<0.001 
Hum-Fc vs sgp130; 2-way ANOVA followed by uncorrected fisher’s test. B - Plasma concentration 
of serum amyloid A (SAA) at day 0 (before angiotensin II and anti-TGFβ infusion) and day 7. C - 
Systolic blood pressure measurement using tail cuff at day 0 and day 7 after angiotensin II and 
anti-TGFβ infusion. D - Survival curves of mice after angiotensin II and anti-TGFβ infusion. *p<0.05 
Hum-Fc vs sgp130; Gehan-Breslow-Wilcoxon test. All data for the generation of the graphs shown 
in Figure 3 were generated in one independent experiment. 
 
Figure 4: Blockage of the IL-6 pathway using anti-IL-6R in the elastase + anti-TGFβ model 
enhances T cell infiltration and rupture of the aorta 
Mice were treated with anti-IL-6R or isotype control (n=12 mice/group) starting one week before 
the application of elastase and the infusion anti-TGFβ. A - Survival curves of mice after the 
application of elastase and the infusion anti-TGFβ. *p<0.05 isotype vs anti-IL6-R; Gehan-Breslow-
Wilcoxon test. B - Representative macroscopic pictures of abdominal aortic aneurysms from mice 
treated with elastase and anti-TGFb and isotope or anti-IL6-R, at day 16.Note that the aneurysm 
from the isotype treated mouse was not ruptured. C - Analysis of the aortic diameter (µm) based 
on the perimeter obtained from aortic cross sections. D - Quantification and representative images 
of collagen content of the aortic wall analysed using Sirius Red staining under polarized light. E, F - 
Quantification and representative images of MPO (D) and CD3 (E) immunofluorescent stainings on 
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aortic cross section. *p<0.05 isotype vs anti-IL-6R; Mann-Whitney test. All data for the generation 
of the graphs shown in Figure 4 were generated in one independent experiment. 
 
Figure 5: Selective blockage of the IL-6 trans-signalling pathway using sgp130 in the 
elastase + anti-TGFβ model increased collagen deposition and prevent aortic rupture 
Notes: Mice were treated with sgp130 or Hum-Fc (n=12 mice/group) starting on the day of the 
application of elastase and the infusion anti-TGFβ. A - Survival curves of mice after the application 
of elastase and the infusion anti-TGFβ. *p<0.05 Hum-Fc vs sgp130; Gehan-Breslow-Wilcoxon test. 
B - Representative macroscopic pictures of abdominal aortic aneurysms from mice treated with 
elastase and anti-TGFb and isotope or anti-IL6-R, at day 16.Note that the aneurysm from the Hum-
Fc treated mouse was ruptured. C - Analysis of the aortic diameter (µm) based on the perimeter 
obtained from aortic cross sections. D - Quantification and representative images of collagen 
content of the aortic wall analysed using Sirius Red staining under polarized light. *p<0.05 Hum-Fc 
vs sgp130; Mann-Whitney test. E, F - Quantification and representative images of Ly6G (D) and 
CD3 (E) immunofluorescent stainings on aortic cross section. All data for the generation of the 
graphs shown in Figure 5 were generated in one independent experiment. 
 
Figure 6: Overview of the IL-6 classical and trans-signalling pathways and their potential 
role in AAA growth 
Notes: A - In “classical” IL-6 signalling (left), the binding of the cytokine IL-6 to the membrane-
bound IL-6 receptor (mIL-6R) leads to the dimerization of its co-receptor gp130, and subsequently, 
triggers downstream signalling in a restricted subset of cells. In IL-6 trans-signalling (right), IL-6 
forms a complex with soluble IL-6 receptor (sIL-6R) that can stimulate cells expressing gp130 even 
in the absence of mIL-6R. The minor allele of a functional variant in the IL6R gene, Asp358Ala 
(rs2228145 A>C) results in more efficient proteolytic cleavage of mIL-6R, thereby reducing levels 
of mIL-6R and classical IL-6 signalling but potentially increasing trans-signalling. B - In mouse 
models of AAA, the blockage of both the classical and trans-signalling pathways with anti-IL6-R 
(i.e. MR16-1, the animal-equivalent of tocilizumab) did not have a conclusive effect on the time to 
aneurysm rupture. C - Specific blockage of the trans-signalling pathway with sgp130 resulted in 
improved survival rates in mouse models of AAA. 
 
 
 
